primidone has been researched along with Abdominal Epilepsy in 35 studies
Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.
primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a patient with focal epilepsy and latent hereditary coproporphyria who had exacerbation of clinical symptoms of porphyria under treatment with valproate and primidone and was then treated with levetiracetam without exacerbation of clinically latent porphyria." | 5.32 | Levetiracetam in focal epilepsy and hepatic porphyria: a case report. ( Meencke, HJ; Paul, F, 2004) |
| "Patients, aged 8-58 years, with partial epilepsy who did not become seizure free on CBZ were randomized to either VPA add-on or PRM add-on." | 2.74 | Comparison of add-on valproate and primidone in carbamazepine-unresponsive patients with partial epilepsy. ( Deckers, CL; Liu, YX; Sun, MZ; Wang, W, 2009) |
| "Gabapentin was started at 400 mg/day and was individually titrated to effective tolerable dose up to 2400 mg/day." | 2.69 | Outcome evaluation of gabapentin as add-on therapy for partial seizures. "NEON" Study Investigators Group. Neurontin Evaluation of Outcomes in Neurological Practice. ( Bruni, J, 1998) |
| "Pretreatment with phenobarbital can minimize the occurrence of intolerable adverse events associated with the introduction of primidone." | 2.69 | The "forgotten" cross-tolerance between phenobarbital and primidone: it can prevent acute primidone-related toxicity. ( Frey, M; Kanner, AM; Parra, J, 2000) |
| "The treatment with primidone alone of 53 epileptic patients with generalized tonic-clonic seizures, partial attacks with elementary symptomatology, and partial fits with complex symptomatology removed them completely in 75, 64." | 2.67 | [Therapeutic and pharmacological monitoring of individual monotherapy of epilepsy with hexamidine]. ( Gromov, SA; Gusel', VA; Khorshev, SK; Smirnov, DP, 1991) |
| "Decreased libido and impotence were more common in patients given primidone." | 2.66 | Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. ( Browne, TR; Collins, JF; Cramer, JA; Delgado-Escueta, AV; Mattson, RH; McCutchen, CB; McNamara, JO; Smith, DB; Treiman, DM; Williamson, PD, 1985) |
| "We report a patient with focal epilepsy and latent hereditary coproporphyria who had exacerbation of clinical symptoms of porphyria under treatment with valproate and primidone and was then treated with levetiracetam without exacerbation of clinically latent porphyria." | 1.32 | Levetiracetam in focal epilepsy and hepatic porphyria: a case report. ( Meencke, HJ; Paul, F, 2004) |
| " Pharmacokinetic data and occurrence of AE were compared between the two groups at the time of the single-dose kinetic study, at the completion of the switchover to CBZ, and 4 weeks after discontinuation of the previous AED." | 1.30 | Rapid switchover to carbamazepine using pharmacokinetic parameters. ( Bourgeois, BF; Hasegawa, H; Hutson, P; Kanner, AM, 1998) |
| "Carbamazepine has no effect on the EEG, in epilepsies with atypical course (atypical benign partial epilepsy, Landau-Kleffner syndrome, epilepsy with continuous spikes and waves during slow sleep [CSWS]) carbamazepine usually has no effect either on the seizures or on the EEG, on the contrary, in some cases both may even get worse." | 1.29 | Treatment of "benign" partial epilepsies of childhood, including atypical forms. ( Gross-Selbeck, G, 1995) |
| "Phenytoin continues to be a very popular drug for most types of seizures, but carbamazepine, used adjunctively until recently, is effective as monotherapy for the control of partial seizures, particularly those of the complex partial variety." | 1.27 | Treatment of the nonconvulsive epilepsies. ( Dreifuss, FE, 1983) |
| "Only when the epilepsy is uncontrolled despite high plasma concentrations which cannot be raised because of side effects, a second drug should be given." | 1.27 | [Pharmacotherapy of epilepsy--current problems and controversies]. ( Schmidt, D, 1983) |
| " (3) Use of well-standardized, yet simplified, mental performance tests in combination with changes in the dosage of medication can help in reaching a compromise between acceptable seizure control and avoidance of excessive slowing of mental activity." | 1.25 | Effects of different dosages of anticonvulsant drugs on mental performance in patients with chronic epilepsy. ( Dekaban, AS; Lehman, EJ, 1975) |
| " Reduction in antiepileptic drug dosage should be carried out as a stepwise procedure over a period of about 2 years." | 1.25 | [A discussion of the curability of childhood epilepsies (author's transl)]. ( Groh, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (74.29) | 18.7374 |
| 1990's | 4 (11.43) | 18.2507 |
| 2000's | 5 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, MZ | 1 |
| Deckers, CL | 1 |
| Liu, YX | 1 |
| Wang, W | 1 |
| Galimberti, CA | 1 |
| Ossola, M | 1 |
| Colnaghi, S | 1 |
| Arbasino, C | 1 |
| Paul, F | 1 |
| Meencke, HJ | 1 |
| Itomi, S | 1 |
| Okumura, A | 1 |
| Ikuta, T | 1 |
| Negoro, T | 1 |
| Watanabe, K | 1 |
| Rowan, AJ | 1 |
| Dreifuss, FE | 1 |
| Schmidt, D | 1 |
| Gross-Selbeck, G | 1 |
| Kanner, AM | 2 |
| Bourgeois, BF | 1 |
| Hasegawa, H | 1 |
| Hutson, P | 1 |
| Bruni, J | 1 |
| Parra, J | 1 |
| Frey, M | 1 |
| Hosokawa, K | 1 |
| Kugoh, T | 1 |
| Otsuki, S | 1 |
| Sutton, G | 1 |
| Kupferberg, HJ | 1 |
| Dekaban, AS | 1 |
| Lehman, EJ | 1 |
| Groh, C | 1 |
| Thomas, JA | 1 |
| Knotts, GR | 1 |
| Gromov, SA | 1 |
| Gusel', VA | 1 |
| Khorshev, SK | 1 |
| Smirnov, DP | 1 |
| Cornaggia, CM | 1 |
| Canevini, MP | 1 |
| Giuccioli, D | 1 |
| Pruneri, C | 1 |
| Canger, R | 1 |
| Klepel, H | 1 |
| Donat, H | 1 |
| Köppe, I | 1 |
| Coulter, DL | 1 |
| Mattson, RH | 2 |
| Cramer, JA | 2 |
| Collins, JF | 2 |
| Smith, DB | 1 |
| Delgado-Escueta, AV | 1 |
| Browne, TR | 1 |
| Williamson, PD | 1 |
| Treiman, DM | 1 |
| McNamara, JO | 1 |
| McCutchen, CB | 1 |
| Reynolds, EH | 1 |
| Laitinen, L | 1 |
| Toivakka, E | 1 |
| Sibley, WA | 1 |
| Deisenhammer, E | 1 |
| Billinghurst, JR | 1 |
| German, GA | 1 |
| Orley, JH | 1 |
| Cereghino, JJ | 1 |
| Brock, JT | 1 |
| Van Meter, JC | 1 |
| Penry, JK | 1 |
| Smith, LD | 1 |
| Fisher, P | 1 |
| Ellenberg, J | 1 |
| Gibberd, FB | 1 |
| Jannasch, R | 1 |
| Kutt, H | 1 |
| Louis, S | 1 |
| Dvilansky, A | 1 |
| Lehman, E | 1 |
| Brunia, CH | 1 |
| Buyze, G | 1 |
| Borkowska, Z | 1 |
| Mazurkowa, K | 1 |
| Wojakowski, A | 1 |
| Popielarska, A | 1 |
| Suffczyńska-Kotowska, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy[NCT00522418] | Phase 4 | 122 participants (Actual) | Interventional | 2006-02-28 | Terminated (stopped due to Insufficient enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Mean change from baseline AEP Score at 12 months
| Intervention | Units on a scale (Mean) |
|---|---|
| VNS Therapy | -6.0 |
| Best Medical Practice | -3.2 |
The Center for Epidemiologic Studies Depression Scale (CES-D) includes 20 items comprising six scales reflecting major dimensions of depression: depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, psychomotor retardation, loss of appetite, and sleep disturbance. Possible range of scores is 0 to 60, higher scores indicate more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline CES-D Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -2.2 |
| Best Medical Practice | 0.5 |
The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) is a 6-item questionnaire validated to screen for depression in people with epilepsy. Scores range from 6 to 24, with higher scores indicating more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline NDDI-E Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -1.0 |
| Best Medical Practice | -0.2 |
Change from baseline in number of AED medications by visit (NCT00522418)
Timeframe: Change from baseline in number of AEDs at 12 months
| Intervention | Number of AEDs Taken (Median) |
|---|---|
| VNS Therapy | 0 |
| Best Medical Practice | 0 |
The Clinical Global Impression scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention Scores range from 1-7: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT00522418)
Timeframe: Mean change from baseline CGI-I Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -0.8 |
| Best Medical Practice | -0.3 |
Percent change in total seizuires per week from baseline at 12 months (NCT00522418)
Timeframe: Mean percent change from baseline in seizure frequency at 12 months
| Intervention | Percent Change (Mean) |
|---|---|
| VNS Therapy | -19.1 |
| Best Medical Practice | -1.0 |
QOLIE-89 contains 17 multi-item measures of overall quality of life, emotional well-being, role limitations due to emotional problems, social support, social isolation, energy/fatigue, worry about seizure, medication effects, health discouragement, work/driving/social function, attention/concentration, language, memory, physical function, pain, role limitations due to physical problems, and health perceptions. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. (NCT00522418)
Timeframe: Mean change from baseline QOLIE-89 Overall Score at 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| VNS Therapy | 5.5 |
| Best Medical Practice | 1.2 |
Response Rate is defined as the percent of participants who are responders. A Responder is defined as participants with a reduction of at least 50% or 75% in seizure frequency from baseline to the seizure count evaluation period. (NCT00522418)
Timeframe: Number of Responders at 12 Months
| Intervention | participants (Number) |
|---|---|
| VNS Therapy | 10 |
| Best Medical Practice | 7 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| VNS Therapy | Best Medical Practice | |
| Baseline Adverse Event Profile Score < 40 | 3.3 | 0.5 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
| Intervention | Units on a Scale (Least Squares Mean) | |
|---|---|---|
| VNS Therapy | Best Medical Practice | |
| Baseline Adverse Event Profile Score >= 40 | 3.3 | 0.7 |
4 reviews available for primidone and Abdominal Epilepsy
| Article | Year |
|---|---|
Diagnosis and treatment of epilepsy.
Topics: Automatism; Benzodiazepines; Carbamazepine; Electroencephalography; Epilepsies, Partial; Epilepsy; E | 1983 |
Anticonvulsants, folic acid, and epilepsy.
Topics: Anemia, Macrocytic; Animals; Anticonvulsants; Blood-Brain Barrier; Chemical Phenomena; Chemistry; Ep | 1973 |
Diagnosis and treatment of epilepsy: overview and general principles.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; | 1974 |
[Antiepileptics. 39].
Topics: Acetazolamide; Adrenocorticotropic Hormone; Aminoglutethimide; Anticonvulsants; Barbiturates; Carbam | 1969 |
7 trials available for primidone and Abdominal Epilepsy
| Article | Year |
|---|---|
Comparison of add-on valproate and primidone in carbamazepine-unresponsive patients with partial epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Drug Therapy, Combination; Epilepsies, Par | 2009 |
Outcome evaluation of gabapentin as add-on therapy for partial seizures. "NEON" Study Investigators Group. Neurontin Evaluation of Outcomes in Neurological Practice.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anti-Anxiety Agents; Anticonvulsants; | 1998 |
The "forgotten" cross-tolerance between phenobarbital and primidone: it can prevent acute primidone-related toxicity.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Child; Child, Preschool; Dizziness; Dose-Response Relation | 2000 |
[Therapeutic and pharmacological monitoring of individual monotherapy of epilepsy with hexamidine].
Topics: Adolescent; Adult; Anticonvulsants; Benzamidines; Dose-Response Relationship, Drug; Drug Monitoring; | 1991 |
Aspects of compliance: taking drugs and keeping clinic appointments.
Topics: Adolescent; Adult; Anticonvulsants; Appointments and Schedules; Carbamazepine; Clinical Trials as To | 1988 |
Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.
Topics: Adolescent; Adult; Aged; Carbamazepine; Clinical Trials as Topic; Double-Blind Method; Epilepsies, P | 1985 |
Evaluation of albutoin as an antiepileptic drug.
Topics: Adolescent; Adult; Allyl Compounds; Analysis of Variance; Anticonvulsants; Appetite; Biopharmaceutic | 1974 |
24 other studies available for primidone and Abdominal Epilepsy
| Article | Year |
|---|---|
Focal epileptic seizures mimicking sleep paralysis.
Topics: Anticonvulsants; Carbamazepine; Diagnosis, Differential; Electroencephalography; Epilepsies, Partial | 2009 |
Levetiracetam in focal epilepsy and hepatic porphyria: a case report.
Topics: Acute Disease; Adult; Anticonvulsants; Comorbidity; Epilepsies, Partial; Female; Humans; Levetiracet | 2004 |
Phenytoin desensitization in a child with symptomatic localization-related epilepsy.
Topics: Anticonvulsants; Child; Drug Therapy, Combination; Epilepsies, Partial; Humans; Male; Phenytoin; Pri | 2007 |
Treatment of the nonconvulsive epilepsies.
Topics: Anticonvulsants; Carbamazepine; Epilepsies, Partial; Epilepsy; Epilepsy, Absence; Humans; Phenobarbi | 1983 |
[Pharmacotherapy of epilepsy--current problems and controversies].
Topics: Adolescent; Adult; Carbamazepine; Child; Child, Preschool; Epilepsies, Partial; Epilepsy; Epilepsy, | 1983 |
Treatment of "benign" partial epilepsies of childhood, including atypical forms.
Topics: Adrenocorticotropic Hormone; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinone | 1995 |
Rapid switchover to carbamazepine using pharmacokinetic parameters.
Topics: Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Administration Schedul | 1998 |
[Clinical study of serum level of dipropylacetic acid sodium (Depakene) by gaschromatography (author's transl)].
Topics: Adolescent; Adult; Child; Child, Preschool; Chromatography, Gas; Drug Therapy, Combination; Epilepsi | 1977 |
Isoniazid as an inhibitor of primidone metabolism.
Topics: Depression, Chemical; Drug Therapy, Combination; Epilepsies, Partial; Female; Humans; Isoniazid; Mid | 1975 |
Effects of different dosages of anticonvulsant drugs on mental performance in patients with chronic epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Chronic Disease; Dose-Response Relationship, Drug; Epilep | 1975 |
[A discussion of the curability of childhood epilepsies (author's transl)].
Topics: Barbiturates; Benzodiazepines; Carbamazepine; Child; Drug Therapy, Combination; Epilepsies, Partial; | 1975 |
Epilepsy and other seizure disorders in children: drug management.
Topics: Acetazolamide; Anticonvulsants; Child; Epilepsies, Partial; Epilepsy; Epilepsy, Absence; Epilepsy, T | 1976 |
Carbamazepine, phenytoin and phenobarbital in drug-resistant partial epilepsies.
Topics: Adolescent; Adult; Carbamazepine; Drug Evaluation; Drug Resistance; Epilepsies, Partial; Epilepsy, T | 1986 |
[Prenatal growth of children of epileptic mothers].
Topics: Anticonvulsants; Birth Weight; Cephalometry; Drug Therapy, Combination; Epilepsies, Partial; Epileps | 1986 |
Withdrawal of barbiturate anticonvulsant drugs: prospective controlled study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Drug Therapy, Combination; Epilepsies, Partial; Epi | 1988 |
Clonazepam (Ro 5-4023) in the treatment of myoclonus epilepsy. Four case reports.
Topics: Adult; Anticonvulsants; Benzodiazepinones; Chlorobenzenes; Diazepam; Drug Therapy, Combination; Elec | 1973 |
[Use of primidone in symptomatic awakening epilepsies].
Topics: Adolescent; Barbiturates; Child; Electroencephalography; Epilepsies, Partial; Epilepsy; Epilepsy, To | 1973 |
The pattern of epilepsy in Uganda.
Topics: Adolescent; Adult; Age Factors; Black People; Child; Child, Preschool; Electroencephalography; Epile | 1973 |
Epilepsy.
Topics: Adult; Child; Epilepsies, Partial; Epilepsy; Epilepsy, Absence; Epilepsy, Temporal Lobe; Epilepsy, T | 1969 |
Anticonvulsant drugs. I. Patho-physiological and pharmacological aspects.
Topics: Acetates; Acetazolamide; Anticonvulsants; Carbamazepine; Diazepam; Dibenzazepines; Electroencephalog | 1972 |
Megaloblastic anemia after anticonvulsive therapy.
Topics: Adult; Anemia, Macrocytic; Anticonvulsants; Epilepsies, Partial; Humans; Male; Phenobarbital; Phenyt | 1972 |
Serum copper levels and epilepsy.
Topics: Acetazolamide; Adolescent; Adult; Age Factors; Amphetamine; Anticonvulsants; Caffeine; Ceruloplasmin | 1972 |
[Results of treatment of epilepsy in children up to 14 years of age].
Topics: Adolescent; Age Factors; Barbiturates; Child; Child, Preschool; Diazepam; Drug Synergism; Electroenc | 1971 |
[Clinical and electroencephalographic evaluation of therapeutic results in post-traumatic epilepsy in children].
Topics: Adolescent; Age Factors; Ambulatory Care; Anticonvulsants; Child; Child, Preschool; Electroencephalo | 1971 |